Alpha emitters are radioactive particles or isotopes that release alpha particles during radioactive decay. They are primarily used in targeted alpha therapy (TAT) for cancer treatment. In TAT, alpha emitter isotopes are attached to molecules that specifically target tumor cells. When internalized by cancer cells, alpha particles can damage DNA and induce cell death. Compared to other radiation therapy, TAT is more effective in treating cancers with minimal damage to surrounding healthy tissues. Some alpha emitters commonly used in cancer therapy include radium-223, actinium-225, bismuth-213, astatine-211 and lead-212. The global Alpha Emitter Market is estimated to be valued at US$ 1,331.0 Mn in 2023 and is expected to exhibit a CAGR of 10.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
The growing applications of alpha emitters in cancer treatment is a major driver of the alpha emitter market. Some key advantages of TAT using alpha emitters over other treatment methods include high efficacy against small tumor sizes, minimal side effects due to localized treatment. Furthermore, alpha particles can cause double-strand DNA breaks which are difficult to repair, resulting in improved treatment outcomes. Alpha emitters also have short tissue penetration range of 50–100 μm, limiting damage to surrounding healthy tissues. Recent advancements in getting consistent supply of alpha emitter isotopes and developing targeted delivery agents is also fueling market growth. However, high production costs and short half-lives of alpha emitter isotopes requiring on-site production are some factors restricting wider market adoption. Ongoing research to develop cost-effective technologies for production and delivery of alpha emitters could unlock significant market potential over the forecast period.
SWOT Analysis
Strength: The alpha emitter market is characterized by its potential for high therapeutic efficacy. Alpha particles have high linear energy transfer which enables them to cause significant DNA damage to cancer cells within a very short range. This property makes alpha emitters highly suited for targeted alpha therapy of cancer. Actinium’s Actimab-A ACT therapy and Telix’s Illuccix have demonstrated significant response rates in clinical trials for various cancers.
Weakness: Alpha emitter production requires specialized facilities with high radioactive safety systems due to the high-energy and short-range nature of alpha particles. This makes large-scale manufacturing challenging. Additionally, any misadministration of alpha particles can potentially cause significant toxicity due to their high potency within a tissue range of only a few cell diameters. This limits their use to targeted delivery scenarios.
Opportunity: The growing field of precision oncology and advancement of targeted drug delivery systems provide significant opportunities for alpha emitters. Conjugation approaches allow delivery of alpha emitters specifically to tumor cells via antibodies or other ligands. This enables potent cancer cell killing while minimizing toxicity to normal tissues. Development of RIT kits also allows greater accessibility and clinical adoption. Untapped areas like neuroendocrine tumors also present opportunities.
Threats: Factors such as supply chain reliability, regulatory approvals, reimbursement coverage, and competition from alternative precision oncology modalities pose threats. Development timelines are also long due to stringent safety requirements for radioisotopes. Commercial viability depends on achieving optimal targeting while balancing manufacturing and treatment costs.
Key Takeaways
The Global Alpha Emitter Market Share is expected to witness high growth over the forecast period driven by its promising efficacy in cancer therapy. The market size for alpha emitters is estimated to reach US$ 2,700 Mn by 2030 at a CAGR of 10%.
Regional analysis: North America currently dominates the alpha emitter market owing to strong government support and presence of key players. The United States FDA has approved several alpha emitter products facilitating clinical adoption. Europe is also a major region fueled by ongoing research in target antigens and drug conjugation techniques. Asia Pacific is expected to be the fastest growing region led by increasing cancer incidence, healthcare investments, and emerging contract manufacturing hubs.
Key players: Key players operating in the alpha emitter market are Actinium Pharmaceutical Inc., Alpha Tau Medical Ltd, Bayer AG, Bracco, Cardinal Health, Eckert & Ziegle, Fusion Pharmaceuticals, IBA Worldwide, NorthStar Medical Radioisotopes (NMR), Orano Group, Viewpoint Molecular Targeting, RadioMedix, Telix Pharmaceuticals Limited., TerraPower, LLC, NIOWAVE Inc. and IONETIX Corporation. Actinium and Telix have commercialized first-of-their-kind targeted alpha therapies while others are engaged.
Get More Insights Here
https://www.trendingwebwire.com/alpha-emitter-market-size-share-growth-outlook-2023/
Comments
0 comment